ISIS 104838-CS7, a double-blind, placebo-controlled, randomized trial of the safety, efficacy and pharmacokinetic profile of ISIS 104838 (TNF [tumour necrosis factor]-alpha antisense oligonucleotide) subcutaneous injections in active rheumatoid arthritis patients

Trial Profile

ISIS 104838-CS7, a double-blind, placebo-controlled, randomized trial of the safety, efficacy and pharmacokinetic profile of ISIS 104838 (TNF [tumour necrosis factor]-alpha antisense oligonucleotide) subcutaneous injections in active rheumatoid arthritis patients

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs ISIS 104838 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 22 Oct 2007 Status changed from in progress to completed.
    • 28 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top